Hims & Hers Stock Rises Thursday on Regulatory Development

Deep News04-17

Shares of Hims & Hers Health Inc. (HIMS) climbed approximately 7% on Thursday. The increase followed comments from Robert F. Kennedy Jr. indicating that the U.S. Food and Drug Administration (FDA) is contemplating adjustments to restrictions on peptide-based medications, a move that could alleviate some regulatory pressure facing the telehealth company.

Kennedy stated that the FDA is considering removing 12 peptide drugs from its list of substances subject to heightened controls. He added that another seven peptide medications will undergo review in July, with further discussions expected by February 2027.

This potential shift is significant because peptide drugs are utilized in certain compounded medications, an area that has faced increased scrutiny from regulators in recent years. For Hims & Hers, any relaxation of rules could improve market sentiment around its weight loss and wellness business segments.

The stock of Hims & Hers had already been demonstrating strong upward momentum, and this latest news further fueled investor interest in the shares. As traders reacted to the prospect of a more favorable regulatory landscape for the company, its stock price extended its recent gains.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106128683?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 03:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106128683","market":"hk","top_or_hot":-1,"title":"Hims & Hers Stock Rises Thursday on Regulatory Development","media":"Deep News","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) climbed approximately 7% on Thursday. The increase followed comments from Robert F. Kennedy Jr. indicating that the U.S. Food and Drug Administration (FDA) is contemplating adjustments to restrictions on peptide-based medications, a move that could alleviate some regulatory pressure facing the telehealth company.</p>\n<p>Kennedy stated that the FDA is considering removing 12 peptide drugs from its list of substances subject to heightened controls. He added that another seven peptide medications will undergo review in July, with further discussions expected by February 2027.</p>\n<p>This potential shift is significant because peptide drugs are utilized in certain compounded medications, an area that has faced increased scrutiny from regulators in recent years. For Hims & Hers, any relaxation of rules could improve market sentiment around its weight loss and wellness business segments.</p>\n<p>The stock of Hims & Hers had already been demonstrating strong upward momentum, and this latest news further fueled investor interest in the shares. As traders reacted to the prospect of a more favorable regulatory landscape for the company, its stock price extended its recent gains.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Stock Rises Thursday on Regulatory Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Stock Rises Thursday on Regulatory Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-17 03:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) climbed approximately 7% on Thursday. The increase followed comments from Robert F. Kennedy Jr. indicating that the U.S. Food and Drug Administration (FDA) is contemplating adjustments to restrictions on peptide-based medications, a move that could alleviate some regulatory pressure facing the telehealth company.</p>\n<p>Kennedy stated that the FDA is considering removing 12 peptide drugs from its list of substances subject to heightened controls. He added that another seven peptide medications will undergo review in July, with further discussions expected by February 2027.</p>\n<p>This potential shift is significant because peptide drugs are utilized in certain compounded medications, an area that has faced increased scrutiny from regulators in recent years. For Hims & Hers, any relaxation of rules could improve market sentiment around its weight loss and wellness business segments.</p>\n<p>The stock of Hims & Hers had already been demonstrating strong upward momentum, and this latest news further fueled investor interest in the shares. As traders reacted to the prospect of a more favorable regulatory landscape for the company, its stock price extended its recent gains.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMY","symbol_name":"Defiance Leveraged Long + Income HIMS ETF","start_time":0,"source_url":"","article_id":"1106128683","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106128683","pubTimestamp":1776367282,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of Hims & Hers Health Inc. (HIMS) climbed approximately 7% on Thursday. The increase followed comments from Robert F. Kennedy Jr. indicating that the U.S. Food and Drug Administration (FDA) is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMY":"Defiance Leveraged Long + Income HIMS ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务","HIYY":"YieldMax HIMS Option Income Strategy ETF"},"translate_title":"Hims&Hers股价周四因监管发展而上涨","themeId":"b2ce105ab495aa94fa9ad67cd213a291","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMYY":1,"HIMS":1,"HIMY":1,"HIMZ":1,"HIYY":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) climbed approximately 7% on Thursday. The increase followed comments from Robert F. Kennedy Jr. indicating that the U.S. Food and Drug Administration (FDA) is contemplating adjustments to restrictions on peptide-based medications, a move that could alleviate some regulatory pressure facing the telehealth company.\nKennedy stated that the FDA is considering removing 12 peptide drugs from its list of substances subject to heightened controls. He added that another seven peptide medications will undergo review in July, with further discussions expected by February 2027.\nThis potential shift is significant because peptide drugs are utilized in certain compounded medications, an area that has faced increased scrutiny from regulators in recent years. For Hims & Hers, any relaxation of rules could improve market sentiment around its weight loss and wellness business segments.\nThe stock of Hims & Hers had already been demonstrating strong upward momentum, and this latest news further fueled investor interest in the shares. As traders reacted to the prospect of a more favorable regulatory landscape for the company, its stock price extended its recent gains.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106128683","isCrawlerRequest":true}